Pharmaceuticals News and Research

RSS

Cambridge Epigenetix introduces TrueMethyl kits for epigenetics industry

Cambridge Epigenetix Ltd., a spin out biosciences company, has announced the launch of its TrueMethyl kits.

15 Jul 2013

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Pfizer Inc. announced today that tofacitinib has been approved for the treatment of rheumatoid arthritis in patients who had an inadequate response to existing therapies in several additional countries around the world, including Switzerland, which is the first European country to receive approval.

15 Jul 2013

FDA approves QIAGEN’s therascreen EGFR test as companion diagnostic for NSCLC patients

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.

From QIAGEN Manchester Limited 15 Jul 2013

Ipsen, Harvard initiate collaboration to discover, develop botulinum toxins for neurologic diseases

Ipsen announced today that it has initiated a research and development collaboration on novel engineered botulinum toxins with Harvard Medical School.

15 Jul 2013

Scientists discover novel method to kill cancer cells

A University of Southampton Professor, in collaboration with colleagues at the BC Cancer Agency Research Centre, have discovered a novel way of killing cancer cells. The research, recently published in the journal Cell, has found a new potential treatment for cancer, which leaves the body's healthy cells undamaged, unlike traditional therapies such as radiotherapy

15 Jul 2013

RXi Pharmaceuticals reports positive results from second Phase 1 study with RXI‑109

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor, and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.

12 Jul 2013

Researchers find new potential treatment for cancer

12 Jul 2013

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

Auspex Pharmaceuticals announced today that the first patient has been enrolled in a multi-center Phase 3 pivotal trial of its lead investigational drug, SD-809 for the treatment of involuntary movements (chorea) associated with Huntington's Disease.

12 Jul 2013

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.

12 Jul 2013

London research fellow says clinical study reports and trial results should be shared publicly

Ben Goldacre, research fellow at the London School of Hygiene and Tropical Medicine, says we need all the evidence to make informed decisions about medicines.

12 Jul 2013

RxVantage releases iPhone application to improve physicians' relationships with medical reps

RxVantage, a healthcare technology company with an innovative cloud-based platform that enables physicians' practices to streamline and improve their relationships with pharmaceutical and other medical sales reps, today announced the release of the RxVantage iPhone application.

11 Jul 2013

Pharmaceutical companies race for new cholesterol drugs, Roche abandons diabetes drug development

A discovery of a rare mutation that affects cholesterol has ignited hopes of a prescription that can help prevent heart attacks. In the meantime, the announcement by Roche could pose more questions about controversial diabetes medicines. Also a federal report warns Americans of using some Internet pharmacies.

11 Jul 2013

Creating a value development plan should be at the forefront of biopharmaceutical market

Mitch DeKoven, Director, HEOR, Real-World Evidence Solutions, IMS Health Inc. and Won Chan Lee, Ph.D., Principal, Health Economics and Outcomes Research, IMS Health, Inc. will present Optimizing Strategic Direction with Systematic Value Development at the Pharmaceutical Market Access Pricing and Reimbursement Conference in San Francisco on October 29, 2013.

11 Jul 2013

MDPV stimulant effects could be more addictive than methamphetamine, say TSRI researchers

Scientists at The Scripps Research Institute have published one of the first laboratory studies of MDPV, an emerging recreational drug that has been sold as “bath salts.”

11 Jul 2013

NPS MedicineWise calls on every Australian to fight against antibiotic resistance

In light of a paper released by the Office of the Chief Scientist today, NPS MedicineWise is calling on every Australian to do their part in the fight against antibiotic resistance in our community.

11 Jul 2013

Scientists discover bacterium that stores biodegradable plastic

In Bolivia, in the largest continuous salt desert in the world, researchers from the Polytechnic University of Catalonia have found a bacterium that stores large amounts of PHB, a prized polymer. This biodegradable plastic is used by the food and pharmaceutical industries, for example to produce nanospheres to transport antibiotics.

11 Jul 2013

Researchers confirm that bath salts could be more addictive than methamphetamine

Scientists at The Scripps Research Institute (TSRI) have published one of the first laboratory studies of MDPV, an emerging recreational drug that has been sold as "bath salts." The TSRI researchers confirmed the drug's powerful stimulant effects in rats and found evidence that it could be more addictive than methamphetamine, one of the most addictive substances to date.

11 Jul 2013

NIH awards Shared Instrumentation Grant to install 3D X-ray microscope at Creighton University

The National Institutes of Health (NIH) have awarded Mohammed Akhter, Ph.D., P.E., professor of medicine at Creighton University School of Medicine and director of the biomechanics laboratory at the Osteoporosis Research Center, a nearly $600,000 Shared Instrumentation Grant to install the area's first high-resolution 3D X-ray Microscope, the Xradia MicroXCT-200.

11 Jul 2013

First Edition: July 10, 2013

Today's early morning highlights from the major news organizations, including articles about House Republican plans to seek a delay in the health law's requirement that nearly all Americans get health insurance.

10 Jul 2013

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

Ohr Pharmaceutical, Inc., a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has enrolled the first 60 patients in the Company's ongoing OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

10 Jul 2013

Pharmaceuticals News and Research

Cambridge Epigenetix introduces TrueMethyl kits for epigenetics industry

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

FDA approves QIAGEN’s therascreen EGFR test as companion diagnostic for NSCLC patients

Ipsen, Harvard initiate collaboration to discover, develop botulinum toxins for neurologic diseases

Scientists discover novel method to kill cancer cells

RXi Pharmaceuticals reports positive results from second Phase 1 study with RXI‑109

Researchers find new potential treatment for cancer

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

London research fellow says clinical study reports and trial results should be shared publicly

RxVantage releases iPhone application to improve physicians' relationships with medical reps

Pharmaceutical companies race for new cholesterol drugs, Roche abandons diabetes drug development

Creating a value development plan should be at the forefront of biopharmaceutical market

MDPV stimulant effects could be more addictive than methamphetamine, say TSRI researchers

NPS MedicineWise calls on every Australian to fight against antibiotic resistance

Scientists discover bacterium that stores biodegradable plastic

Researchers confirm that bath salts could be more addictive than methamphetamine

NIH awards Shared Instrumentation Grant to install 3D X-ray microscope at Creighton University

First Edition: July 10, 2013

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence